Oncology Business Management

Deliberations are complete and final votes cast for the winners of the 2015 Giants of Cancer Care Award recognizing individuals who have achieved landmark success in the field of oncology.

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

For Gladys Rodriguez, MD, a practicing oncologist for 24 years, the daily schedule is filled with calls to payers and hours spent at the computer typing up electronic health records.

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

The FDA has granted a breakthrough therapy designation to crizotinib as a potential treatment for patients with ROS1-positive non–small cell lung cancer.

The president of Medicine & Science at Cancer Treatment Centers of America and editor-in-chief of OncologyLive magazine argues the FDA's recent approval of olaparib (Lynparza) for women with BRCA-mutated advanced ovarian cancer is too restrictive and should be offered to many more patients.

With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.

The Senate has joined the House of Representatives in passing legislation to repeal the Sustainable Growth Rate (SGR) formula and replace it with the Medicare Access and CHIP Reauthorization Act of 2015 (HR 2).

The new Value-Based Payment Modifier program from the Centers for Medicare & Medicaid Services may not be high on the list of concerns for the average oncologist, but its impact could be huge.

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients.

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Given a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.

The growing popularity of high-deductible health insurance plans has created a range of increasing pressures on oncologists and hematologists.

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.